TODARO, MARIA
TODARO, MARIA
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
2015-01-01 Abate, F.; Todaro, M.; Van Der Krogt, J.-A.; Boi, M.; Landra, I.; Machiorlatti, R.; Tabbò, F.; Messana, K.; Abele, C.; Barreca, A.; Novero, D.; Gaudiano, M.; Aliberti, S.; Di Giacomo, F.; Tousseyn, T.; Lasorsa, E.; Crescenzo, R.; Bessone, L.; Ficarra, E.; Acquaviva, A.; Rinaldi, A.; Ponzoni, M.; Longo, D.L.; Aime, S.; Cheng, M.; Ruggeri, B.; Piccaluga, P.P.; Pileri, S.; Tiacci, E.; Falini, B.; Pera-Gresely, B.; Cerchietti, L.; Iqbal, J.; Chan, W.C.; Shultz, L.D.; Kwee, I.; Piva, R.; Wlodarska, I.; Rabadan, R.; Bertoni, F.; Inghirami, G.
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells
2019-01-01 Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
2012-01-01 Tabbó F; Barreca A; Piva R; Inghirami G; The European T-Cell Lymphoma Study Group; including; Riccardo Bruna; Daniele Corino; Diego Cortese; Ramona Crescenzo; Giuditta Cuccuru; Filomena di Giacomo; Alessandro Fioravanti; Marco Ladetto; Indira Landra; Katia Messana; Rodolfo Machiorlatti; Barbara Martinoglio; Enzo Medico; Marta Mossino; Elisa Pellegrino; Maria Todaro; Paola Campisi; Luigi Chiusa; Annalisa Chiappella; Domenico Novero; Umberto Vitolo; Francesco Abate; Andrea Acquaviva; Elisa Ficarra; Roberto Freilone; Marco Chilosi; Alberto Zamó; Fabio Facchetti; Silvia Lonardi; Anna De Chiara; Franco Fulciniti; Claudio Doglioni; Maurilio Ponzoni; Luca Agnelli; Antonino Neri; Katia Todoerti; Claudio Agostinelli; Pier Paolo Piccaluga; Stefano Pileri; Brunangelo Falini; Enrico Tiacci; Peter Van Loo; Thomas Tousseyn; Christiane De Wolf-Peeters; Eva Geissinger; Hans Konrad Muller-Hermelink; Andreas Rosenwald; Miguel Angel Piris; Maria E. Rodriguez; Francesco Bertoni; Michela Boi; Ivo Kwee;)
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
2023-01-01 Vitale, Candida; Griggio, Valentina; Todaro, Maria; Riganti, Chiara; Jones, Rebecca; Boccellato, Elia; Perutelli, Francesca; Arruga, Francesca; Vaisitti, Tiziana; Efremov, Dimitar G; Deaglio, Silvia; Landesman, Yosef; Bruno, Benedetto; Coscia, Marta
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma
2015-01-01 Crescenzo, Ramona; Abate, Francesco; Lasorsa, Elena; Tabbo', Fabrizio; Gaudiano, Marcello; Chiesa, Nicoletta; Di Giacomo, Filomena; Spaccarotella, Elisa; Barbarossa, Luigi; Ercole, Elisabetta; Todaro, Maria; Boi, Michela; Acquaviva, Andrea; Ficarra, Elisa; Novero, Domenico; Rinaldi, Andrea; Tousseyn, Thomas; Rosenwald, Andreas; Kenner, Lukas; Cerroni, Lorenzo; Tzankov, Alexander; Ponzoni, Maurilio; Paulli, Marco; Weisenburger, Dennis; Chan, Wing C.; Iqbal, Javeed; Piris, Miguel A.; Zamo', Alberto; Ciardullo, Carmela; Rossi, Davide; Gaidano, Gianluca; Pileri, Stefano; Tiacci, Enrico; Falini, Brunangelo; Shultz, Leonard D.; Mevellec, Laurence; Vialard, Jorge E.; Piva, Roberto; Bertoni, Francesco; Rabadan, Raul; Inghirami, Giorgio
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells
2020-01-01 Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M.
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target
2016-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, Fr; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
2020-01-01 Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia
2018-01-01 Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Magic pills: new oral drugs to treat chronic lymphocytic leukemia
2017-01-01 Vitale, Candida; Griggio, Valentina; Todaro, Maria; Salvetti, Chiara; Boccadoro, Mario; Coscia, Marta
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.
2013-01-01 Michela Boi; Andrea Rinaldi; Ivo Kwee; Paola Bonetti; Maria Todaro; Fabrizio Tabbò; Roberto Piva; Paola M. V. Rancoita; András Matolcsy; Botond Timar; Thomas Tousseyn; Socorro Maria Rodríguez-Pinilla; Miguel A. Piris; Sílvia Beà; Elias Campo; Govind Bhagat; Steven H. Swerdlow; Andreas Rosenwald; Maurilio Ponzoni; Ken H. Young; Pier Paolo Piccaluga; Reinhard Dummer; Stefano Pileri; Emanuele Zucca; Giorgio Inghirami; Francesco Bertoni
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2016-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2018-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE
2017-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target
2018-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2018-01-01 Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2020-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE
2018-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells
2019-01-01 Vitale, Candida; Todaro, Maria; Griggio, Valentina; Salvetti, Chiara; Riganti, Chiara; Landesman, Yosef; Boccadoro, Mario; Coscia, Marta
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance
2016-01-01 Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Landesman, Y; Coscia, M
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation | 2015 | Abate, F.; Todaro, M.; Van Der Krogt, J.-A.; Boi, M.; Landra, I.; Machiorlatti, R.; Tabbò, F.; Messana, K.; Abele, C.; Barreca, A.; Novero, D.; Gaudiano, M.; Aliberti, S.; Di Giacomo, F.; Tousseyn, T.; Lasorsa, E.; Crescenzo, R.; Bessone, L.; Ficarra, E.; Acquaviva, A.; Rinaldi, A.; Ponzoni, M.; Longo, D.L.; Aime, S.; Cheng, M.; Ruggeri, B.; Piccaluga, P.P.; Pileri, S.; Tiacci, E.; Falini, B.; Pera-Gresely, B.; Cerchietti, L.; Iqbal, J.; Chan, W.C.; Shultz, L.D.; Kwee, I.; Piva, R.; Wlodarska, I.; Rabadan, R.; Bertoni, F.; Inghirami, G. | |
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells | 2019 | Todaro Maria, Griggio Valentina, Salvetti Chiara, Riganti Chiara, Landesman Yosef, Boccadoro Mario, Vitale Candida, Coscia Marta | |
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma | 2012 | Tabbó F; Barreca A; Piva R; Inghirami G; The European T-Cell Lymphoma Study Group; including; Riccardo Bruna; Daniele Corino; Diego Cortese; Ramona Crescenzo; Giuditta Cuccuru; Filomena di Giacomo; Alessandro Fioravanti; Marco Ladetto; Indira Landra; Katia Messana; Rodolfo Machiorlatti; Barbara Martinoglio; Enzo Medico; Marta Mossino; Elisa Pellegrino; Maria Todaro; Paola Campisi; Luigi Chiusa; Annalisa Chiappella; Domenico Novero; Umberto Vitolo; Francesco Abate; Andrea Acquaviva; Elisa Ficarra; Roberto Freilone; Marco Chilosi; Alberto Zamó; Fabio Facchetti; Silvia Lonardi; Anna De Chiara; Franco Fulciniti; Claudio Doglioni; Maurilio Ponzoni; Luca Agnelli; Antonino Neri; Katia Todoerti; Claudio Agostinelli; Pier Paolo Piccaluga; Stefano Pileri; Brunangelo Falini; Enrico Tiacci; Peter Van Loo; Thomas Tousseyn; Christiane De Wolf-Peeters; Eva Geissinger; Hans Konrad Muller-Hermelink; Andreas Rosenwald; Miguel Angel Piris; Maria E. Rodriguez; Francesco Bertoni; Michela Boi; Ivo Kwee;) | |
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia | 2023 | Vitale, Candida; Griggio, Valentina; Todaro, Maria; Riganti, Chiara; Jones, Rebecca; Boccellato, Elia; Perutelli, Francesca; Arruga, Francesca; Vaisitti, Tiziana; Efremov, Dimitar G; Deaglio, Silvia; Landesman, Yosef; Bruno, Benedetto; Coscia, Marta | |
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma | 2015 | Crescenzo, Ramona; Abate, Francesco; Lasorsa, Elena; Tabbo', Fabrizio; Gaudiano, Marcello; Chiesa, Nicoletta; Di Giacomo, Filomena; Spaccarotella, Elisa; Barbarossa, Luigi; Ercole, Elisabetta; Todaro, Maria; Boi, Michela; Acquaviva, Andrea; Ficarra, Elisa; Novero, Domenico; Rinaldi, Andrea; Tousseyn, Thomas; Rosenwald, Andreas; Kenner, Lukas; Cerroni, Lorenzo; Tzankov, Alexander; Ponzoni, Maurilio; Paulli, Marco; Weisenburger, Dennis; Chan, Wing C.; Iqbal, Javeed; Piris, Miguel A.; Zamo', Alberto; Ciardullo, Carmela; Rossi, Davide; Gaidano, Gianluca; Pileri, Stefano; Tiacci, Enrico; Falini, Brunangelo; Shultz, Leonard D.; Mevellec, Laurence; Vialard, Jorge E.; Piva, Roberto; Bertoni, Francesco; Rabadan, Raul; Inghirami, Giorgio | |
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells | 2020 | Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M. | |
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target | 2016 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, Fr; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia | 2020 | Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta | |
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia | 2018 | Griggio V, Vitale C, Todaro M, Mauro FR, Salvetti C, Pietrasanta D, Vincelli ID, Scarfo L, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
Magic pills: new oral drugs to treat chronic lymphocytic leukemia | 2017 | Vitale, Candida; Griggio, Valentina; Todaro, Maria; Salvetti, Chiara; Boccadoro, Mario; Coscia, Marta | |
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. | 2013 | Michela Boi; Andrea Rinaldi; Ivo Kwee; Paola Bonetti; Maria Todaro; Fabrizio Tabbò; Roberto Piva; Paola M. V. Rancoita; András Matolcsy; Botond Timar; Thomas Tousseyn; Socorro Maria Rodríguez-Pinilla; Miguel A. Piris; Sílvia Beà; Elias Campo; Govind Bhagat; Steven H. Swerdlow; Andreas Rosenwald; Maurilio Ponzoni; Ken H. Young; Pier Paolo Piccaluga; Reinhard Dummer; Stefano Pileri; Emanuele Zucca; Giorgio Inghirami; Francesco Bertoni | |
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2016 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M | |
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2018 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE | 2017 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target | 2018 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2018 | Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2020 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE | 2018 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Coscia, M | |
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells | 2019 | Vitale, Candida; Todaro, Maria; Griggio, Valentina; Salvetti, Chiara; Riganti, Chiara; Landesman, Yosef; Boccadoro, Mario; Coscia, Marta | |
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance | 2016 | Todaro, M; Griggio, V; Vitale, C; Salvetti, C; Riganti, C; Boccadoro, M; Landesman, Y; Coscia, M |